253 related articles for article (PubMed ID: 22886613)
1. REO-001: A phase I trial of percutaneous intralesional administration of reovirus type 3 dearing (Reolysin®) in patients with advanced solid tumors.
Morris DG; Feng X; DiFrancesco LM; Fonseca K; Forsyth PA; Paterson AH; Coffey MC; Thompson B
Invest New Drugs; 2013 Jun; 31(3):696-706. PubMed ID: 22886613
[TBL] [Abstract][Full Text] [Related]
2. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors.
Gollamudi R; Ghalib MH; Desai KK; Chaudhary I; Wong B; Einstein M; Coffey M; Gill GM; Mettinger K; Mariadason JM; Mani S; Goel S
Invest New Drugs; 2010 Oct; 28(5):641-9. PubMed ID: 19572105
[TBL] [Abstract][Full Text] [Related]
3. Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.
Harrington KJ; Karapanagiotou EM; Roulstone V; Twigger KR; White CL; Vidal L; Beirne D; Prestwich R; Newbold K; Ahmed M; Thway K; Nutting CM; Coffey M; Harris D; Vile RG; Pandha HS; Debono JS; Melcher AA
Clin Cancer Res; 2010 Jun; 16(11):3067-77. PubMed ID: 20484020
[TBL] [Abstract][Full Text] [Related]
4. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer.
Vidal L; Pandha HS; Yap TA; White CL; Twigger K; Vile RG; Melcher A; Coffey M; Harrington KJ; DeBono JS
Clin Cancer Res; 2008 Nov; 14(21):7127-37. PubMed ID: 18981012
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.
Karapanagiotou EM; Roulstone V; Twigger K; Ball M; Tanay M; Nutting C; Newbold K; Gore ME; Larkin J; Syrigos KN; Coffey M; Thompson B; Mettinger K; Vile RG; Pandha HS; Hall GD; Melcher AA; Chester J; Harrington KJ
Clin Cancer Res; 2012 Apr; 18(7):2080-9. PubMed ID: 22316603
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of REOLYSIN
Mahalingam D; Fountzilas C; Moseley J; Noronha N; Tran H; Chakrabarty R; Selvaggi G; Coffey M; Thompson B; Sarantopoulos J
Cancer Chemother Pharmacol; 2017 Apr; 79(4):697-703. PubMed ID: 28289863
[TBL] [Abstract][Full Text] [Related]
7. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.
Comins C; Spicer J; Protheroe A; Roulstone V; Twigger K; White CM; Vile R; Melcher A; Coffey MC; Mettinger KL; Nuovo G; Cohn DE; Phelps M; Harrington KJ; Pandha HS
Clin Cancer Res; 2010 Nov; 16(22):5564-72. PubMed ID: 20926400
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors.
Villalona-Calero MA; Lam E; Otterson GA; Zhao W; Timmons M; Subramaniam D; Hade EM; Gill GM; Coffey M; Selvaggi G; Bertino E; Chao B; Knopp MV
Cancer; 2016 Mar; 122(6):875-83. PubMed ID: 26709987
[TBL] [Abstract][Full Text] [Related]
9. A phase I trial and viral clearance study of reovirus (Reolysin) in children with relapsed or refractory extra-cranial solid tumors: a Children's Oncology Group Phase I Consortium report.
Kolb EA; Sampson V; Stabley D; Walter A; Sol-Church K; Cripe T; Hingorani P; Ahern CH; Weigel BJ; Zwiebel J; Blaney SM
Pediatr Blood Cancer; 2015 May; 62(5):751-8. PubMed ID: 25728527
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma.
Sborov DW; Nuovo GJ; Stiff A; Mace T; Lesinski GB; Benson DM; Efebera YA; Rosko AE; Pichiorri F; Grever MR; Hofmeister CC
Clin Cancer Res; 2014 Dec; 20(23):5946-55. PubMed ID: 25294913
[TBL] [Abstract][Full Text] [Related]
11. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer.
Lolkema MP; Arkenau HT; Harrington K; Roxburgh P; Morrison R; Roulstone V; Twigger K; Coffey M; Mettinger K; Gill G; Evans TR; de Bono JS
Clin Cancer Res; 2011 Feb; 17(3):581-8. PubMed ID: 21106728
[TBL] [Abstract][Full Text] [Related]
12. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
[TBL] [Abstract][Full Text] [Related]
13. The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors.
Kapadia R; Coffey MC
Methods; 2010 Dec; 52(4):301-6. PubMed ID: 20801221
[TBL] [Abstract][Full Text] [Related]
14. Clinical trials involving the oncolytic virus, reovirus: ready for prime time?
Black AJ; Morris DG
Expert Rev Clin Pharmacol; 2012 Sep; 5(5):517-20. PubMed ID: 23121273
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.
Roulstone V; Khan K; Pandha HS; Rudman S; Coffey M; Gill GM; Melcher AA; Vile R; Harrington KJ; de Bono J; Spicer J
Clin Cancer Res; 2015 Mar; 21(6):1305-12. PubMed ID: 25424857
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
17. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.
Laurie SA; Bell JC; Atkins HL; Roach J; Bamat MK; O'Neil JD; Roberts MS; Groene WS; Lorence RM
Clin Cancer Res; 2006 Apr; 12(8):2555-62. PubMed ID: 16638865
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.
Hu JC; Coffin RS; Davis CJ; Graham NJ; Groves N; Guest PJ; Harrington KJ; James ND; Love CA; McNeish I; Medley LC; Michael A; Nutting CM; Pandha HS; Shorrock CA; Simpson J; Steiner J; Steven NM; Wright D; Coombes RC
Clin Cancer Res; 2006 Nov; 12(22):6737-47. PubMed ID: 17121894
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas.
Forsyth P; Roldán G; George D; Wallace C; Palmer CA; Morris D; Cairncross G; Matthews MV; Markert J; Gillespie Y; Coffey M; Thompson B; Hamilton M
Mol Ther; 2008 Mar; 16(3):627-32. PubMed ID: 18253152
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial.
White CL; Twigger KR; Vidal L; De Bono JS; Coffey M; Heinemann L; Morgan R; Merrick A; Errington F; Vile RG; Melcher AA; Pandha HS; Harrington KJ
Gene Ther; 2008 Jun; 15(12):911-20. PubMed ID: 18323793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
